LIBTAYO
Google image searchProduct monograph
Active ingredient
cemiplimab, 350 MG/7 ML
DIN: 02487144
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription / Schedule D
Company: REGENERON CANADA COMPANY
Date: 11-JUN-2024
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FF — PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors (ATC, ATC/DDD)
- L01FF06 — CEMIPLIMAB (ATC/DDD)
